文献速递妇科

靶向维持治疗时代复发性铂敏感卵巢癌的二次肿瘤细胞减灭术与肿瘤学结局

Secondary cytoreductive surgery and oncologic outcomes in the era of targeted maintenance therapy for recurrent, platinum-sensitive ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2024-04-18

本研究回顾性比较了FDA批准PARP抑制剂和贝伐珠单抗维持治疗前后,因铂敏感复发性卵巢癌首次复发接受二次肿瘤细胞减灭术患者的肿瘤学结局。共纳入245例患者,批准前131例(53%)、批准后114例(47%)。批准后PARPi维持使用从3.8%增至27%,贝伐珠单抗从1.5%增至12%(均P<0.001)。中位PFS2分别为19和20.1个月。批准后组中,完全肉眼切除者1年PFS2率为84.5%,残留病灶者为56.2%;3年PFS2率分别为31.3%和12.5%(P=0.001)。

要点

  • 二次肿瘤细胞减灭术中完全肉眼切除与更优的PFS2相关。
  • FDA批准PARPi和贝伐珠单抗维持治疗后,二者使用率显著增加。
  • 批准前后中位PFS2分别为19个月和20.1个月。

核心结论

  • 二次肿瘤细胞减灭术中的完全肉眼切除与次优切除相比,与改善的PFS2相关。
  • 需要前瞻性随机试验来阐明随着更多治疗手段出现,二次肿瘤细胞减灭术的作用。

研究设计与样本

  • 回顾性研究,纳入2013年1月1日至2020年1月1日因铂敏感复发性卵巢癌首次复发接受二次肿瘤细胞减灭术的患者。
  • 排除既往因复发接受化疗、肠梗阻手术和姑息性手术者。
  • 以2017年1月为界将数据二分,对应FDA批准PARPi和贝伐珠单抗用于复发性卵巢癌维持治疗的时间。
  • 共245例患者,批准前131例(53%),批准后114例(47%)。
  • 主要终点为第二次无进展生存期(PFS2),采用Kaplan-Meier法估计。

主要发现

  • 批准前后两组高级别浆液性肿瘤分别占83%和90%(p=0.13)。
  • 可检测患者中,批准前后分别有27%(32/120)和28%(32/113)存在有害BRCA1/2改变(p=0.88)。
  • 批准前后无病间期分别为:6-12个月16%和18%;12-30个月56%和59%;>30个月28%和24%(p=0.73)。
  • 批准前后分别有85%和86%的患者达到完全肉眼切除(CGR;p>0.99)。
  • 批准后PARPi维持使用从3.8%增至27%(p<0.001),贝伐珠单抗从1.5%增至12%(p<0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To compare oncologic outcomes of secondary cytoreductive surgery (SCS) before and after FDA approval of Poly(ADP-ribose) polymerase inhibitor (PARPi) and bevacizumab maintenance therapies for platinum-sensitive recurrent ovarian cancer (PS-ROC). METHODS: Patients who underwent SCS for first recurrence of PS-ROC from 1/1/2013-1/1/2020 were identified. Exclusion criteria included prior chemotherapy for recurrence, bowel obstruction procedures, and palliative surgery. Data were dichotomized pre/post 1/2017, relative to FDA approval of PARPi and bevacizumab maintenance for ROC. Second progression-free survival (PFS2), the primary endpoint, was estimated using Kaplan-Meier method. RESULTS: Overall, 245 patients underwent SCS-131 (53%) pre- and 114 (47%) post-approval. Most patients had high-grade serous tumors (83% and 90%, respectively; p = 0.13). Deleterious BRCA1/2 alterations were identified in 27% (32/120) and 28% (32/113) of tested patients, respectively (p = 0.88). Disease-free intervals pre- and post-approval were: 6-12 months, 16% and 18%; 12-30 months, 56% and 59%; and >30 months, 28% and 24%, respectively (p = 0.73). Overall, 85% and 86% of patients, respectively, achieved complete gross resection (CGR; p > 0.99). PARPi maintenance use increased from 3.8% to 27% (p < 0.001) following approval, and bevacizumab from 1.5% to 12% (p < 0.001). Median PFS2 was 19 and 20.1 months, respectively. In the post group, 1-year PFS2 rate was 84.5% (95% CI, 75.7-90.4%) for patients with CGR vs 56.2% (95% CI, 29.5-76.2%) for those with residual disease; 3-year PFS2 rates were 31.3% (95% CI, 21.6-41.4%) and 12.5% (95% CI, 2.1-32.8%), respectively (p = 0.001). CONCLUSIONS: CGR during SCS is associated with improved PFS2 compared to suboptimal resection. Prospective randomized trials are warranted to elucidate the role of SCS as more therapeutics become available.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Ehmann S, Lam C, Zhou Q, et al. Secondary cytoreductive surgery and oncologic outcomes in the era of targeted maintenance therapy for recurrent, platinum-sensitive ovarian cancer. Gynecol Oncol. 2024. PMID: 38640773. doi:10.1016/j.ygyno.2024.03.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。